Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Target Price of $66.00

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $66.00.

A number of equities research analysts have recently weighed in on GUTS shares. Weiss Ratings downgraded shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Craig Hallum began coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They set a “buy” rating and a $48.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GUTS. Nantahala Capital Management LLC acquired a new stake in shares of Fractyl Health during the 2nd quarter valued at $8,968,058. 683 Capital Management LLC increased its holdings in Fractyl Health by 30.1% in the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after purchasing an additional 1,397,620 shares in the last quarter. Bank of America Corp DE bought a new position in Fractyl Health in the second quarter valued at about $4,791,000. Pale Fire Capital SE raised its position in Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after purchasing an additional 2,711,103 shares during the last quarter. Finally, Catalio Capital Management LP raised its position in Fractyl Health by 5.3% in the fourth quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock valued at $12,082,000 after purchasing an additional 277,630 shares during the last quarter.

Fractyl Health Price Performance

NASDAQ GUTS opened at $4.16 on Tuesday. The business has a fifty day moving average price of $7.02 and a two-hundred day moving average price of $8.08. Fractyl Health has a fifty-two week low of $3.78 and a fifty-two week high of $29.34. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.62) by $0.18. As a group, research analysts anticipate that Fractyl Health will post -6.32 EPS for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.